HGH Fragment 176-191

Fat Loss / Metabolic Peptideresearch

Also known as: HGH Frag, Fragment 176-191, GH Frag, Tyr-hGH177-191

A modified fragment of human growth hormone (amino acids 176-191) that specifically promotes fat metabolism and lipolysis without the growth-promoting or diabetogenic effects of full HGH.

Overview

HGH Fragment 176-191 is a synthetic peptide consisting of the C-terminal portion of human growth hormone, spanning amino acids 176-191, with a tyrosine modification at position 177. This specific region of HGH was identified as the portion responsible for the hormone's fat-burning properties. Researchers at Monash University in Australia demonstrated that this fragment retains the lipolytic (fat-burning) activity of growth hormone while lacking its growth-promoting, insulin-resistant, and IGF-1-raising effects. The fragment works by mimicking the way natural growth hormone regulates fat metabolism — stimulating lipolysis and inhibiting lipogenesis. It is closely related to AOD 9604, which is a further-modified version of the same fragment. HGH Fragment 176-191 has been popular in the bodybuilding and biohacking communities for targeted fat loss without the side effects associated with full growth hormone administration.

Mechanism of Action

HGH Fragment 176-191 acts on fat metabolism: (1) Stimulates lipolysis (fat breakdown) by activating beta-3 adrenergic receptor-mediated pathways in adipose tissue; (2) Inhibits lipogenesis (new fat formation) by blocking fatty acid synthase activity; (3) Promotes release of stored fatty acids from adipocytes for oxidation; (4) Does not bind to the full growth hormone receptor, avoiding IGF-1 stimulation; (5) Does not affect glucose metabolism or insulin sensitivity (no diabetogenic effect); (6) Preferentially targets visceral and abdominal fat deposits; (7) May enhance cartilage regeneration independent of IGF-1.

Molecular Formula

C78H123N21O20S2

Molecular Weight

1815.10 g/mol

Sequence

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

Dosage Protocols

Dose Range

250mcg500mcg

Frequency

Once to twice daily

Route

subcutaneous

Cycle Length

8-12 weeks

Best administered on an empty stomach, typically morning and/or pre-bed. Avoid eating for 30 minutes post-injection to maximize efficacy. Inject into abdominal subcutaneous fat. Can be combined with exercise for enhanced results.

Source: Community protocols and preclinical research

Side Effects

EffectSeverity
Injection site irritationmild
Drowsinessmild
Headachemild
Hypoglycemia symptomsmild

Pros & Cons

Targets fat loss specifically without the growth-promoting or diabetogenic effects of full HGH

Does not raise IGF-1 levels, reducing theoretical cancer risk associated with growth hormone

No negative impact on glucose metabolism or insulin sensitivity

Preferentially targets visceral/abdominal fat, the most metabolically dangerous fat depot

Limited clinical evidence — most data from animal studies and community reports

Requires fasted administration for optimal effect, limiting convenience

Effects are modest without concurrent diet and exercise — not a magic bullet

Very similar to AOD 9604, which has more research — may not offer distinct advantages

Research Studies

Legal Status

Not FDA-approved. Available as a research chemical. Banned by WADA. Subject to regulatory scrutiny in some jurisdictions. AOD 9604 (related) has more regulatory history.

Related Peptides